Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD.

Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15. Review.

PMID:
30885693
2.

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.

Rockstroh JK, Asmuth D, Pantaleo G, Clotet B, Podzamczer D, van Lunzen J, Arastéh K, Mitsuyasu R, Peters B, Silvia N, Jolliffe D, Ökvist M, Krogsgaard K, Sommerfelt MA.

PLoS One. 2019 Jan 30;14(1):e0210965. doi: 10.1371/journal.pone.0210965. eCollection 2019.

3.

CD32 Expression of Different Memory T Cell Subpopulations in the Blood and Lymph Nodal Tissue of HIV Patients and Healthy Controls Correlates With Immune Activation.

Wittner M, Dunay GA, Kummer S, Bockhorn M, Hüfner A, Schmiedel S, Degen O, van Lunzen J, Eberhard JM, Schulze Zur Wiesch J.

J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):345-349. doi: 10.1097/QAI.0000000000001622.

PMID:
29293157
4.

Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.

Arribas JR, DeJesus E, van Lunzen J, Zurawski C, Doroana M, Towner W, Lazzarin A, Nelson M, McColl D, Andreatta K, Swamy R, Szwarcberg J, Nguyen T.

HIV Clin Trials. 2017 May;18(3):118-125. doi: 10.1080/15284336.2017.1330440. Epub 2017 May 30. Erratum in: HIV Clin Trials. 2018 Aug;19(4):163.

PMID:
28555519
5.

Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression.

Kim ES, Ackermann C, Tóth I, Dierks P, Eberhard JM, Wroblewski R, Scherg F, Geyer M, Schmidt RE, Beisel C, Bockhorn M, Haag F, van Lunzen J, Schulze Zur Wiesch J.

J Leukoc Biol. 2017 May;101(5):1263-1271. doi: 10.1189/jlb.5A0816-346R. Epub 2017 Feb 13.

PMID:
28193736
6.

Circulating CXCR5+CXCR3+PD-1lo Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth.

Martin-Gayo E, Cronin J, Hickman T, Ouyang Z, Lindqvist M, Kolb KE, Schulze Zur Wiesch J, Cubas R, Porichis F, Shalek AK, van Lunzen J, Haddad EK, Walker BD, Kaufmann DE, Lichterfeld M, Yu XG.

JCI Insight. 2017 Jan 26;2(2):e89574. doi: 10.1172/jci.insight.89574.

7.

Brief Report: Increased Frequency of CD39+ CD56bright Natural Killer Cells in HIV-1 Infection Correlates With Immune Activation and Disease Progression.

Dierks P, Wroblewski R, Eberhard JM, Martrus G, Degen O, Hertling S, Schmiedel S, Lunemann S, Hüfner A, Lohse AW, Altfeld M, van Lunzen J, Schulze Zur Wiesch J.

J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):467-472. doi: 10.1097/QAI.0000000000001266.

PMID:
27930600
8.

Reduced CD161+ MAIT cell frequencies in HCV and HIV/HCV co-infection: Is the liver the heart of the matter?

Eberhard JM, Kummer S, Hartjen P, Hüfner A, Diedrich T, Degen O, Lohse AW, van Lunzen J, Schulze Zur Wiesch J.

J Hepatol. 2016 Dec;65(6):1261-1263. doi: 10.1016/j.jhep.2016.07.031. Epub 2016 Aug 1. No abstract available.

PMID:
27492054
9.

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kümmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J; PARTNER Study Group.

JAMA. 2016 Jul 12;316(2):171-81. doi: 10.1001/jama.2016.5148. Erratum in: JAMA. 2016 Aug 9;316(6):667. JAMA. 2016 Nov 15;316(19):2048.

PMID:
27404185
10.

International AIDS Society global scientific strategy: towards an HIV cure 2016.

Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F; International AIDS Society Towards a Cure Working Group, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen ÉA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J.

Nat Med. 2016 Aug;22(8):839-50. doi: 10.1038/nm.4108. Epub 2016 Jul 11.

11.

Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype.

Bhardwaj S, Ahmad F, Wedemeyer H, Cornberg M, Schulze Zur Wiesch J, van Lunzen J, Sarin SK, Schmidt RE, Meyer-Olson D.

Virol J. 2016 Apr 18;13:67. doi: 10.1186/s12985-016-0507-5.

12.

High proportion of HIV late presenters at an academic tertiary care center in northern Germany confirms the results of several cohorts in Germany: time to put better HIV screening efforts on the national agenda?

Schäfer G, Kreuels B, Schmiedel S, Hertling S, Hüfner A, Degen O, van Lunzen J, Schulze Zur Wiesch J.

Infection. 2016 Jun;44(3):347-52. doi: 10.1007/s15010-016-0880-4. Epub 2016 Feb 25.

PMID:
26914449
13.

Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity.

Karpinski J, Hauber I, Chemnitz J, Schäfer C, Paszkowski-Rogacz M, Chakraborty D, Beschorner N, Hofmann-Sieber H, Lange UC, Grundhoff A, Hackmann K, Schrock E, Abi-Ghanem J, Pisabarro MT, Surendranath V, Schambach A, Lindner C, van Lunzen J, Hauber J, Buchholz F.

Nat Biotechnol. 2016 Apr;34(4):401-9. doi: 10.1038/nbt.3467. Epub 2016 Feb 22.

PMID:
26900663
14.

Linker-Region Modified Derivatives of the Deoxyhypusine Synthase Inhibitor CNI-1493 Suppress HIV-1 Replication.

Schröder M, Kolodzik A, Windshügel B, Krepstakies M, Priyadarshini P, Hartjen P, van Lunzen J, Rarey M, Hauber J, Meier C.

Arch Pharm (Weinheim). 2016 Feb;349(2):91-103. doi: 10.1002/ardp.201500323. Epub 2016 Jan 3.

PMID:
26725082
15.

Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.

van Lunzen J, Antinori A, Cohen CJ, Arribas JR, Wohl DA, Rieger A, Rachlis A, Bloch M, Segal-Maurer S, Garner W, Porter D, Bosse M, Piontkowsky D, Chuck SK, De-Oertel S.

AIDS. 2016 Jan;30(2):251-9. doi: 10.1097/QAD.0000000000000911.

PMID:
26684822
16.

Parallel assessment of Th17 cell frequencies by surface marker co-expression versus ex vivo IL-17 production in HIV-1 infection.

Dunay GA, Tóth I, Eberhard JM, Degen O, Tolosa E, van Lunzen J, Hauber J, Schulze Zur Wiesch J.

Cytometry B Clin Cytom. 2016 Nov;90(6):486-492. doi: 10.1002/cyto.b.21352. Epub 2016 Feb 18.

17.

Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.

van Lunzen J, Pozniak A, Gatell JM, Antinori A, Klauck I, Serrano O, Baakili A, Osiyemi O, Sevinsky H, Girard PM.

J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):538-43. doi: 10.1097/QAI.0000000000000904.

18.

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M, Madruga JV, Brunetta J, Shamblaw D, DeJesus E, Orkin C, Wohl DA, Brar I, Stephens JL, Girard PM, Huhn G, Plummer A, Liu YP, Cheng AK, McCallister S; GS-US-292-0109 team.

Lancet Infect Dis. 2016 Jan;16(1):43-52. doi: 10.1016/S1473-3099(15)00348-5. Epub 2015 Nov 2.

PMID:
26538525
19.

Patient-adapted, specific activation of HIV-1 by customized TAL effectors (TALEs), a proof of principle study.

Geissler R, Hauber I, Funk N, Richter A, Behrens M, Renner I, Chemnitz J, Hofmann-Sieber H, Baum H, van Lunzen J, Boch J, Hauber J, Behrens SE.

Virology. 2015 Dec;486:248-54. doi: 10.1016/j.virol.2015.09.018. Epub 2015 Oct 27.

20.

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.

Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, Kulagin V, Givens N, de Oliveira CF, Brennan C; FLAMINGO study team.

Lancet HIV. 2015 Apr;2(4):e127-36. doi: 10.1016/S2352-3018(15)00027-2. Epub 2015 Mar 10. Erratum in: Lancet HIV. 2015 Apr;2(4):e126.

PMID:
26424673
21.

[Sex differences in infectious diseases and their clinical consequences].

Beisel C, van Lunzen J, Lohse AW, Addo MM, Altfeld M.

Dtsch Med Wochenschr. 2015 Sep;140(18):1385-90. doi: 10.1055/s-0041-104246. Epub 2015 Sep 11. Review. German.

PMID:
26360954
23.

From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany.

Schmidt D, Kollan C, Stoll M, Stellbrink HJ, Plettenberg A, Fätkenheuer G, Bergmann F, Bogner JR, van Lunzen J, Rockstroh J, Esser S, Jensen BE, Horst HA, Fritzsche C, Kühne A, an der Heiden M, Hamouda O, Bartmeyer B; ClinSurv Study Group.

BMC Public Health. 2015 Mar 17;15:252. doi: 10.1186/s12889-015-1598-4.

24.

Low SAMHD1 expression following T-cell activation and proliferation renders CD4+ T cells susceptible to HIV-1.

Ruffin N, Brezar V, Ayinde D, Lefebvre C, Schulze Zur Wiesch J, van Lunzen J, Bockhorn M, Schwartz O, Hocini H, Lelievre JD, Banchereau J, Levy Y, Seddiki N.

AIDS. 2015 Mar 13;29(5):519-30. doi: 10.1097/QAD.0000000000000594.

25.

CMV specific cytokine release assay in whole blood is optimized by combining synthetic CMV peptides and toll like receptor agonists.

Dammermann W, Bochmann D, Bentzien F, Komorowski L, Steinhagen K, Ullrich S, van Lunzen J, Lüth S.

J Immunol Methods. 2014 Dec 1;414:82-90. doi: 10.1016/j.jim.2014.10.011. Epub 2014 Oct 30.

PMID:
25450001
26.

Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .

Zoufaly A, Jochum J, Hammerl R, Nassimi N, Raymond Y, Burchard GD, Schmiedel S, Drexler JF, Campbell NK, Taka N, Awasom C, Metzner KJ, van Lunzen J, Feldt T.

J Antimicrob Chemother. 2015 Mar;70(3):922-5. doi: 10.1093/jac/dku470. Epub 2014 Nov 26.

27.

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO.

Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, Kulagin V, Givens N, Brennan C, de Oliveira CF.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19490. doi: 10.7448/IAS.17.4.19490. eCollection 2014.

28.

CD161+ MAIT cells are severely reduced in peripheral blood and lymph nodes of HIV-infected individuals independently of disease progression.

Eberhard JM, Hartjen P, Kummer S, Schmidt RE, Bockhorn M, Lehmann C, Balagopal A, Hauber J, van Lunzen J, Schulze zur Wiesch J.

PLoS One. 2014 Nov 4;9(11):e111323. doi: 10.1371/journal.pone.0111323. eCollection 2014.

29.

Reduced expression of Blimp-1 in memory B cells in patients with HIV-1 infection suggests distinct roles of this molecule for B and T cell regulation.

Beisel C, Toth I, van Lunzen J, Schulze Zur Wiesch J.

AIDS. 2014 Oct 23;28(16):2489-91. doi: 10.1097/QAD.0000000000000448. No abstract available.

PMID:
25265234
30.

Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study.

Hoffmann C, Hentrich M, Gillor D, Behrens G, Jensen B, Stoehr A, Esser S, van Lunzen J, Krznaric I, Müller M, Oette M, Hensel M, Thoden J, Fätkenheuer G, Wyen C.

HIV Med. 2015 Apr;16(4):261-4. doi: 10.1111/hiv.12200. Epub 2014 Sep 23.

31.

[Cost of Illness of HIV Patients under Anteretroviral Therapy in Germany - Results of the 48-Week Interim Analysis of the Prospective Multicentre Observational Study 'CORSAR'].

Kuhlmann A, Mittendorf T, Hower M, Heiken H, Gerschmann S, Klauke S, Lutz T, Bogner J, Degen O, van Lunzen J, Bachmann C, Stellbrink HJ, Schmidt W, Leistner I, Mahlich J, Ranneberg B, Stoll M.

Gesundheitswesen. 2015 Jun;77(6):e133-42. doi: 10.1055/s-0034-1381993. Epub 2014 Sep 23. German.

PMID:
25247761
32.

German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients.

Beisel C, Heuer M, Otto B, Jochum J, Schmiedel S, Hertling S, Degen O, Lüth S, van Lunzen J, Schulze Zur Wiesch J.

AIDS Res Ther. 2014 Jul 1;11:16. doi: 10.1186/1742-6405-11-16. eCollection 2014.

33.

Sex differences in infectious diseases-common but neglected.

van Lunzen J, Altfeld M.

J Infect Dis. 2014 Jul 15;209 Suppl 3:S79-80. doi: 10.1093/infdis/jiu159.

PMID:
24966193
34.

Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.

Wehmeyer MH, Eißing F, Jordan S, Röder C, Hennigs A, Degen O, Hüfner A, Hertling S, Schmiedel S, Sterneck M, van Lunzen J, Lohse AW, Schulze zur Wiesch J, Lüth S.

BMC Gastroenterol. 2014 May 5;14:87. doi: 10.1186/1471-230X-14-87.

35.

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S; ING114915 Study Team.

Lancet. 2014 Jun 28;383(9936):2222-31. doi: 10.1016/S0140-6736(14)60084-2. Epub 2014 Apr 1. Erratum in: Lancet. 2015 Jun 27;385(9987):2576.

PMID:
24698485
36.

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.

Palella FJ Jr, Fisher M, Tebas P, Gazzard B, Ruane P, Van Lunzen J, Shamblaw D, Flamm J, Ebrahimi R, Porter D, White K, Hindman J, Elbert E, De-Oertel S, Fralich T.

AIDS. 2014 Jan 28;28(3):335-44. doi: 10.1097/QAD.0000000000000087. Erratum in: AIDS. 2014 Aug 24;28(13):1999-2001.

PMID:
24670520
37.

Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM; TBNET.

Eur Respir J. 2014 Jul;44(1):23-63. doi: 10.1183/09031936.00188313. Epub 2014 Mar 23.

38.

Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals.

Zoufaly A, Kiepe JG, Hertling S, Hüfner A, Degen O, Feldt T, Schmiedel S, Kurowski M, van Lunzen J.

HIV Med. 2014 Sep;15(8):449-57. doi: 10.1111/hiv.12134. Epub 2014 Feb 24.

39.

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamczer D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B.

Lancet Infect Dis. 2014 Apr;14(4):291-300. doi: 10.1016/S1473-3099(13)70343-8. Epub 2014 Feb 11.

40.

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.

Cohen C, Wohl D, Arribas JR, Henry K, Van Lunzen J, Bloch M, Towner W, Wilkins E, Ebrahimi R, Porter D, White K, Walker I, Chuck S, De-Oertel S, Fralich T.

AIDS. 2014 Apr 24;28(7):989-97. doi: 10.1097/QAD.0000000000000169.

PMID:
24508782
41.

Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe.

Zoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren J, Reiss P, Jevtovic D, Machala L, Zangerle R, Mocroft A, Van Lunzen J; EuroSIDA in EuroCoord.

PLoS One. 2014 Jan 31;9(1):e87160. doi: 10.1371/journal.pone.0087160. eCollection 2014.

42.

High HIV prevalence among children presenting for general consultation in rural Cameroon.

Zoufaly A, Hammerl R, Sunjoh F, Jochum J, Nassimi N, Awasom C, Tayong G, Sauter F, Schmiedel S, van Lunzen J, Burchard G, Feldt T.

Int J STD AIDS. 2014 Sep;25(10):742-4. doi: 10.1177/0956462413518762. Epub 2014 Jan 27.

PMID:
24469969
43.

Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients.

Xicoy B, Ribera JM, Müller M, García O, Hoffmann C, Oriol A, Hentrich M, Grande C, Wasmuth JC, Esteve J, van Lunzen J, Del Potro E, Knechten H, Brunet S, Mayr C, Escoda L, Schommers P, Alonso N, Vall-Llovera F, Pérez M, Morgades M, González J, Fernández A, Thoden J, Gökbuget N, Hoelzer D, Fätkenheuer G, Wyen C; PETHEMA Group and German HIV Lymphoma Cohort.

Leuk Lymphoma. 2014 Oct;55(10):2341-8. doi: 10.3109/10428194.2013.878933. Epub 2014 Feb 25.

PMID:
24397614
44.

Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.

Harrer T, Plettenberg A, Arastéh K, Van Lunzen J, Fätkenheuer G, Jaeger H, Janssens M, Burny W, Collard A, Roman F, Loeliger A, Koutsoukos M, Bourguignon P, Lavreys L, Voss G.

Vaccine. 2014 May 7;32(22):2657-65. doi: 10.1016/j.vaccine.2013.10.030. Epub 2013 Oct 19.

45.

Hepatitis E virus infections in HIV-infected patients in Ghana and Cameroon.

Feldt T, Sarfo FS, Zoufaly A, Phillips RO, Burchard G, van Lunzen J, Jochum J, Chadwick D, Awasom C, Claussen L, Drosten C, Drexler JF, Eis-Hübinger AM.

J Clin Virol. 2013 Sep;58(1):18-23. doi: 10.1016/j.jcv.2013.05.004. Epub 2013 Jun 4.

PMID:
23743346
46.

Decreased frequency of CD73+CD8+ T cells of HIV-infected patients correlates with immune activation and T cell exhaustion.

Tóth I, Le AQ, Hartjen P, Thomssen A, Matzat V, Lehmann C, Scheurich C, Beisel C, Busch P, Degen O, Lohse AW, Eiermann T, Fätkenheuer G, Meyer-Olson D, Bockhorn M, Hauber J, van Lunzen J, Schulze Zur Wiesch J.

J Leukoc Biol. 2013 Oct;94(4):551-61. doi: 10.1189/jlb.0113018. Epub 2013 May 24.

PMID:
23709688
47.

Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative.

Rodger AJ, Bruun T, Vernazza P, Collins S, Estrada V, Van Lunzen J, Corbelli GM, Phillips AN, Lundgren JD; PARTNER Study Group.

Antivir Ther. 2013;18(3):285-7. doi: 10.3851/IMP2609. Epub 2013 Apr 24.

PMID:
23615792
48.

Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis?

Schulze Zur Wiesch J, van Lunzen J.

J Infect Dis. 2013 Jul 15;208(2):362-3. doi: 10.1093/infdis/jit159. Epub 2013 Apr 9. No abstract available.

PMID:
23570847
49.

Vγ2Vδ2 T cells are skewed toward a terminal differentiation phenotype in untreated HIV infection.

Hartjen P, Meyer-Olson D, Lehmann C, Stellbrink HJ, van Lunzen J, Schulze zur Wiesch J.

J Infect Dis. 2013 Jul;208(1):180-2. doi: 10.1093/infdis/jit141. Epub 2013 Apr 1. No abstract available.

PMID:
23547141
50.

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.

Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, Miller M, Vella S, Schmitz JE, Ahlers J, Richman DD, Sekaly RP.

Lancet. 2013 Jun 15;381(9883):2109-17. doi: 10.1016/S0140-6736(13)60104-X. Epub 2013 Mar 29. Review.

Supplemental Content

Loading ...
Support Center